Clinical Trial Update: Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial update reports immunogenicity and safety findings for a novel adjuvanted hepatitis B vaccine in adults awaiting liver transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Novel Adjuvanted Hepatitis B vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B | Phase 3 | Status: COMPLETED